Performance of diagnostic mammography differs in the United States and Denmark by Jensen, Allan et al.
PERFORMANCE OF DIAGNOSTIC MAMMOGRAPHY DIFFERS IN
THE UNITED STATES AND DENMARK
Allan Jensen1,2, Berta M. Geller3, Charlotte C. Gard4,5, Diana L. Miglioretti4,5, Bonnie
Yankaskas6, Patricia A. Carney7,8, Robert D. Rosenberg9, Ilse Vejborg10, and Elsebeth
Lynge1
1Institute of Public Health, University of Copenhagen, Øster Farimagsgade 5, PO box 2099,
DK-1014 Copenhagen K, Denmark
2Institute of Cancer Epidemiology, Danish Cancer Society, Strandboulevarden 49, DK-2100
Copenhagen O, Denmark
3University of Vermont, College of Medicine, Departments of Family Medicine and Radiology,
Burlington, VT 05401-3444, US
4Group Health Research Institute, Biostatistics Unit, Seattle, WA 98101, US
5University of Washington, Department of Biostatistics, Seattle, WA, 98109, US
6University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7510, US
7Norris Cotton Cancer Centre, Dartmouth-Hitchcock Medical Centre, Department of Community
and Family Medicine, Dartmouth Medical School, Lebanon, NH, US
8Oregon Health and Science University, School of Medicine, Department of Family Medicine,
Portland, OR, US
9Department of Radiology, University of New Mexico - HSC, Albuquerque, NM 87131, US
10Centre of Diagnostic Imaging, University Hospital Copenhagen, Blegdamsvej 9, DK-2100
Copenhagen Ø, Denmark
Abstract
Diagnostic mammography is the primary imaging modality to diagnose breast cancer. However,
few studies have evaluated variability in diagnostic mammography performance in communities,
and none has done so between countries. We compared diagnostic mammography performance in
community-based settings in the United States and Denmark. The performance of 93,585
diagnostic mammograms from 180 facilities contributing data to the U.S. Breast Cancer
Surveillance Consortium (BCSC) from 1999 through 2001 was compared to that of all 51,313
diagnostic mammograms performed at Danish clinics in 2000. We used the imaging workup’s
final assessment to determine sensitivity, specificity, and an estimate of accuracy: area under the
receiver-operating characteristics (ROC) curve (AUC). Diagnostic mammography had slightly
higher sensitivity in the United States (85%) than in Denmark (82%). In contrast, it had higher
specificity in Denmark (99%) than in the United States (93%). The AUC was high in both
countries: U.S. 0.91; and Denmark 0.95. Denmark’s higher accuracy may result from
supplementary ultrasound examinations, which are provided to 74% of Danish women but only
37% to 52% of U.S. women. In addition, Danish mammography facilities specialize in either
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diagnosis or screening, possibly leading to greater diagnostic mammography expertise in facilities
dedicated to symptomatic patients. Performance of community-based diagnostic mammography
settings varied markedly between the two countries, indicating that it can be further optimized.
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INTRODUCTION
Unlike screening mammography, diagnostic mammography is used to identify breast
cancers in women who have a breast symptom such as a lump. Diagnostic mammography is
most often undertaken in combination with a clinical examination and supplemental breast
ultrasound or other imaging (1). In all countries with mammography screening, the
prevalence of breast cancer is approximately 10-fold higher and the stage of disease is more
advanced in women receiving diagnostic mammography than in those receiving screening
mammography (2).
Only a limited number of studies have examined the interpretive performance (i.e.,
sensitivity and specificity) of diagnostic mammography. Four studies examined the
performance of diagnostic mammography in single facilities (3–6), whereas five additional
studies have evaluated performance at the community level: four from the United States
using data collected by the Breast Cancer Surveillance Consortium (BCSC) (2;7–10) and
one from Denmark (11). The provision of diagnostic mammography differs between the
United States and Denmark. In the United States, most mammography facilities offer both
screening and diagnostic mammography and distinguish between the two services (12). By
contrast, the organized mammography screening programmes in Denmark are run by clinics
dedicated to screening, while women with breast symptoms are examined in clinics
dedicated to diagnostic mammography (11).
In the United States, facilities participating in the BCSC, a population-based consortium of
community mammography registries (13), prospectively collect data on all diagnostic
mammograms, which are pooled at a statistical coordinating centre. Denmark has a
complete database of diagnostic mammograms for 2000 (11).
Using these databases, the objective of this study was to compare the performance of
diagnostic mammography across two community-based settings: in Denmark and in the
United States. Our study is the first to evaluate variability in diagnostic performance
between countries with differing systems of delivering mammography services. Our results
suggest that distinctions between the diagnostic mammography programs in these countries
may explain the variability in performance between them and suggest ways to deliver health
services more effectively.
MATERIAL AND METHODS
In the United States, a diagnostic mammogram may include standard medio-lateral-oblique
(MLO) and cranio-caudal (CC) projections, tangential views, or other special views to
evaluate an area of clinical or radiographic concern such as spot compression or spot
compression with magnification. When selecting a view, the proximity of the area of
concern to the image receptor is considered (14). Breast ultrasound is also indicated in the
“evaluation and characterization of palpable masses and other breast-related signs and/or
symptoms” (15). Fine-needle aspiration (FNA) of the area of clinical concern, or to rule out
simple cysts found at ultrasound, is not used routinely in the United States; however, some
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radiologists use FNA instead of ultrasound to rule out cysts (16). In the United States, some
symptomatic women also receive clinical breast examination (CBE), but it is not universal.
In Denmark, examination of women with breast concerns or symptoms includes obtaining a
clinical history, CBE, diagnostic mammography using MLO and CC projections often
supplemented with a medio-lateral (ML) projection, magnification, or spot compression
projections. Indications for ultrasound are broader in Denmark than in the United States. In
most clinics in Denmark, whole-breast ultrasound scanning is used for all palpable masses
and all mammographic “probably benign” findings, suspicious abnormalities, and
abnormalities highly suggestive of cancer. In case of suspicious abnormalities and
abnormalities highly suggestive of cancer, the contra-lateral breast is also scanned with
ultrasound. In Denmark, FNA or core needle biopsy (CNB) is used to investigate women
presenting with all types of solid palpable breast lesions and also for non-palpable breast
lesions with uncertain, suspicious, or malignant features on the diagnostic mammography or
ultrasound examination (11;17;18).
We defined a diagnostic mammography as an examination of one woman, including at least
one mammographic exposure performed to evaluate a breast symptom or clinical concern.
We did not include diagnostic mammography performed for the additional evaluation or
short-interval follow-up of a routine screening mammogram. If more than one diagnostic
mammography was performed during the study period, we used the result of only the last
examination to evaluate the performance. We included examinations performed with
ultrasound or magnetic resonance imaging (MRI) (for both populations, MRI was rarely
used around 2000) only if they were used as part of the additional workup of a diagnostic
mammogram - not if they were the only imaging modality performed.
Data Sources
The United States—Data on diagnostic mammography in the United States were
obtained from seven mammography registries that form the BCSC (13): 1) Carolina
Mammography Registry, North Carolina 2) Group Health Cooperative, Seattle, Washington,
3) New Hampshire Mammography Network, 4) San Francisco Mammography Registry,
California 5) Vermont Breast Cancer Surveillance System, 6) Colorado Mammography
Project, Denver, and 7) New Mexico Mammography Project, Albuquerque. The BCSC
uniformly collects data pertaining to mammography performance across diverse settings and
populations (19). Data include patient demographic and clinical information, mammogram
interpretation, biopsy results, and cancer diagnoses in the defined catchment areas of the
participating facilities. Mammography results are reported using the categories of the
American College of Radiology’s Breast Imaging Reporting and Data System (BI-RADS®)
(20). Cancer cases are ascertained through active follow-up and through linkages with state
tumour registries or Surveillance, Epidemiology, and End Result (SEER) programs. Most
registries supplement the capture of cancer cases through linkages with pathology databases.
Cancer ascertainment from the tumour and SEER registries has been found to be at least
94% complete (2). We included diagnostic mammograms performed from January 1, 1999
through December 31, 2001, on women aged 20–89 without a history of breast cancer at 180
BCSC facilities. Each mammography registry and the statistical coordinating center have
received institutional review board approval for either active or passive consenting processes
or a waiver of consent to enroll participants, link data, and perform analytic studies. All
procedures comply with the Health Insurance Portability and Accountability Act, and all
registries and the statistical coordinating center have received a Federal Certificate of
Confidentiality and other protection for the identities of women, physicians, and facilities
that are subjects of this research.
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Denmark—In Denmark, diagnostic mammography is available free to all Danish citizens
after referral from a general practitioner. We collected data on all diagnostic mammograms
performed in 2000 at all 32 public clinics, 12 private clinics, and 3 private hospitals in
Denmark (11). Data were merged into a single database. Each record included the residence
region, clinic, laterality of examined breast, date of examination, type of imaging and
diagnosis, and the woman’s unique personal identification number, which is used for all
registration in Denmark. We used the same inclusion criteria for diagnostic mammograms in
Denmark as for those in the United States. The Danish Data Protection Agency gave
permission to undertake the study.
Classification of examinations as positive or negative for analysis
The United States—We used the final recorded assessment at the end of all imaging
workup and within 3 months of the initial diagnostic mammography to evaluate the
performance of a sequence of imaging that began with the diagnostic mammogram. Most of
the examination records from the BCSC registries stated whether additional mammographic
imaging or ultrasound was performed on the same day as the diagnostic mammographic
examination and whether the result was used to arrive at the BI-RADS assessment; however,
some registries did not completely capture whether an ultrasound was performed.
Mammography examinations given a final BI-RADS assessment of 4 (suspicious
abnormality) or 5 (highly suggestive of cancer) at the end of the imaging workup were
considered positive (20). Examinations with a BI-RADS assessment of 3 (probably benign)
or 0 (need additional imaging evaluation) and with a recommendation for biopsy, FNA, or
surgical consultation were re-coded to BI-RADS code 4 (N=1, 354, 1.4 %). We classified as
negative those mammograms given a final BI-RADS assessment of 1 (negative), 2 (benign),
or 3 (probably benign, without a recommendation for biopsy, FNA, or surgical consultation)
(20). Mammography examinations with a final BI-RADS assessment of 0 with a
recommendation for additional imaging, non-specified workup, or missing recommendation
were considered to be missing the final assessment, and thus were excluded from the
analysis (N=1, 807, 1.9 %).
Denmark—Danish radiologists report on the outcome of a diagnostic mammography in
free text. We collected these radiological reports for all Danish diagnostic mammograms in
our database and scored the imaging outcome (combined evaluation of mammography and
ultrasound, if performed) into 5 categories similar to the categorisation used in the BI-RADS
classification system (11;20). The final assessments were based on the descriptors used in
the reports (10). Normal reports were automatically scored 1; clear benign findings, 2; clear
malignant reports, 5; and the remaining reports that were not obviously benign or malignant
were scored into categories 3, 4, and 5 by three experienced radiologists (Ilse Vejborg and 2
experienced colleagues) who were blinded to the final diagnosis (cancer or no cancer).
Mammography examinations scored as a final BI-RADS assessment of 4 or 5 at the end of
the imaging workup were considered positive. We considered mammography examinations
scored with a final assessment of 1, 2, or 3 as negative. As with the BCSC data, we used the
final recorded assessment to evaluate the performance of a sequence of imaging that began
with the diagnostic mammogram.
As a sensitivity analysis, we varied our definition of positive and negative in several ways.
First, we considered all Danish mammograms with a BI-RADS 3 to be positive, given the
proportion of cancer in these mammograms resembles that of mammograms given a BI-
RADS 4 assessment in the United States. Second, we considered U.S. mammograms with a
BI-RADS assessment of 0 or 3 with a recommendation for biopsy, FNA, or surgical
consultation to be negative instead of positive.
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To determine subsequent breast cancer status for U.S. women, the cohort of examined
women was linked to regional cancer registries and pathology databases to determine cancer
outcomes. Subsequent breast cancer status for Danish women was found by linkage with the
Danish Cancer Register and the Danish Registry of Pathology, using the unique Danish
personal identification numbers. We defined incident breast cancer as all invasive breast
carcinoma or ductal carcinoma in situ (DCIS) that occurred within 1 year (365 days) of the
initial diagnostic mammogram.
Performance measures and statistical analysis
For each woman, the BI-RADS assessment score and breast cancer status after 1 year were
combined to identify true-positive (positive BI-RADS assessment with breast cancer), true-
negative (negative BI-RADS assessment without a breast cancer), false-positive (positive
BI-RADS assessment without breast cancer) and false-negative (negative BI-RADS with
breast cancer) diagnostic mammography examinations. On this basis, sensitivity was defined
as the percentage of positive examinations among women diagnosed with breast cancer
[true-positive/(true-positive + false-negative)], and specificity was defined as the percentage
of negative examinations among women without a breast cancer diagnosis [true-negative/
(true-negative + false-positive)]. We also used receiver operating characteristic (ROC)
analysis to take into account the trade-off between sensitivity and specificity. For the ROC
analysis, the modified BI-RADS assessment categories were ordered (1, 2, 3, 4, and 5) in
accordance with an increasing likelihood of a breast cancer diagnosis. Accuracy was defined
as the area under the receiver operating characteristic curve (AUC), with a value of 0.50
indicating purely random performance and 1.00 indicating the maximal value possible.
RESULTS
The study included 93,585 diagnostic mammograms from women at seven BCSC
mammography registries (180 facilities) in the United States and 51,313 diagnostic
mammograms from women at 47 clinics in Denmark (Table 1). In both the United States
and Denmark, most diagnostic mammograms were performed in women aged 40–49 and
50–59 years. The proportion of U.S. women aged 40–49 years with a diagnostic
mammography exceeded the proportion for the corresponding age group of Danish women
(34% versus 27%); the reverse was true for women age 50–59 years (22% versus 29%).
However, mean age at diagnostic mammogram was not markedly different between women
in the two countries: 49.2 years in the United States and 49.8 years in Denmark. Based on
BCSC registries with near complete capture of ultrasound, we estimated that ultrasound was
used to make an assessment for 37% to 52% of all women. In contrast, ultrasound was used
in 74% of examinations in Denmark (Table 1).
In the United States, 9,325 (10.0%) diagnostic mammograms were positive and 84 260
(90.0%) were negative In Denmark, 3,462 (6.7%) diagnostic mammograms were positive,
and 47,851 (93.3%) were negative. The number of women with invasive breast cancer and
DCIS diagnosed within 1 year of follow-up was 3,773 in the United States and 3,406 in
Denmark, resulting in a lower proportion of women with breast cancer in the United States
(4.0%) than in Denmark (6.6%). Despite the heavier burden of breast cancers in Denmark, a
markedly higher proportion (91%) of the examined women in Denmark had normal/benign
findings than did those in the United States (82%). Use of the BI-RADS categories
“suspicious abnormality” and “highly suggestive of malignancy” somewhat compensated for
this difference, because the proportion of women with these findings was lower in Denmark
(6.7%) than in the United States (10.0%). However, the category “probably benign” which
accounted for 8.0% of the examined women in the United States, and only for 2.5% in
Jensen et al. Page 5













Denmark, accounted for most of the difference. The proportion of women with cancer
within each BI-RADS category also varied between the two countries, especially for BI-
RADS codes 3, 4, and 5, where the proportions of women with breast cancer were markedly
higher in Denmark than in the United States (Table 2).
The sensitivity of diagnostic mammography was higher in the United States data at 85.0%
compared with 82.4% in the Danish data (Table 3). In contrast, the specificity was higher in
Denmark with 98.6% compared with 93.2% in the United States. The area under the ROC
curve (AUC) based on the 5-point BI-RADS assessment scale was higher in Denmark, 0.95,
than in the United States, 0.91 (Table 3 and Figure 1).
If Danish mammograms given a BI-RADS 3 are considered positive, Denmark’s sensitivity
increases to 89.2%, higher than the U.S. sensitivity of 85.0%, and Denmark’s specificity
decreases to 96.5%, which is still higher than the U.S. specificity of 93.2%. Similarly, If
U.S. mammograms with a BI-RADS assessment of 0 or 3 with a recommendation for
biopsy, FNA, or surgical consultation are considered negative instead of positive, the U.S.
sensitivity decreases to 81.6%, which is closer to the Danish sensitivity of 82.4%; however,
the specificity only increases to 94.6%, which is still much lower than the Danish specificity
of 98.6%.
DISCUSSION
Our study is the first to evaluate variability in performance of diagnostic mammography
between the United States and a European country. This comparative study revealed
different approaches in outcome coding and methods of workup between the two
populations on performance of diagnostic mammography. Despite these reservations, the
study suggests performance differences exist. Within 1 year of follow-up, the sensitivity was
2.6 percentage-points higher in the United States than in Denmark (85.0% compared to
82.4%), and the specificity was 5.4 percentage-points higher in Denmark than in the United
States (98.6% compared to 93.2%). These differences in opposite directions suggest
differences in the threshold used to recommend biopsy in the United States and Denmark;
however, the overall AUC based on the 5-point BI-RADS assessment scale was higher in
Denmark than in the United States, 0.95 versus 0.91, suggesting there is also a difference in
accuracy. Accuracy may be higher in Denmark than in the United States due to
supplementary ultrasound examinations provided to 74% of women in Denmark compared
with only approximately 37% to 52% of women in the United States. In addition, Danish
mammography facilities specialize in either diagnosis or screening, possibly leading to
greater diagnostic mammography expertise in facilities dedicated to symptomatic patients.
One of the reasons for the observed differences in performance is that needle biopsy and
ultrasound are sometimes used differently in Denmark and the United States for the
evaluation of suspected fibroadenomas and cysts. A fibroadenoma usually has a
characteristic appearance on ultrasound but not on mammography. In the United States, a
palpable fibroadenoma-appearing mass will usually be classified as BI-RADS 4a (low
suspicion of malignancy but warrants biopsy) or 4b (Intermediate suspicion of malignancy
but warrants biopsy). This is a positive mammography, with a recommendation for a biopsy
which decreases specificity. In the U.S. it is routine to biopsy what is believed to be a
fibroadenoma on the small chance that it is a cancer while in Denmark during the time
period of this study radiologists were willing to slightly lower their sensitivity to reduce the
number of benign biopsies. Currently, however, Danish radiologists biopsy all solid palpable
fibroadenomas.
Jensen et al. Page 6













Differences in coding may also account for some of the observed differences in
performance. In the United States, diagnostic mammograms with a BI-RADS assessment of
0 (needs additional evaluation) or 3 (probably benign) with a recommendation for FNA,
biopsy, or surgical consultation are considered positive, whereas in Denmark, all diagnostic
mammograms with clearly benign signs were given BI-RADS codes 1–3, even if a biopsy
was recommended. This results in a higher specificity in Denmark and a slightly lower
sensitivity, given that some findings with benign features are cancer.
Another difference between the two countries is that some radiologists in the United States
use FNA instead of ultrasound to rule our cysts. Mammograms with a BI-RADS assessment
of 0 (needs additional evaluation) or 3 (probably benign) with a recommendation for FNA
are considered positive exams. In Denmark, ultrasound examinations are used to rule out
cysts, and these examinations are scored as negative. However, only 1.1% of U.S.
mammograms had a final recommendation of FNA, so this could only account for a small
proportion of the differences.
Data from BCSC included only mammograms individually coded as being performed for the
evaluation of a clinical breast symptom or concern, whereas all mammograms from
diagnostic mammography clinics in Denmark were included, allowing for a very minor
contamination with opportunistic screening (21). For 2000, breast cancer incidence rates
were 97 per 100,000 [World Health Organization (WHO) World Standard Population] white
U.S. women, and 84 per 100,000 (World Standard Population) Danish women (22).
Nevertheless, the Danish data set included a higher proportion of women with breast cancer.
This may reflect that a high proportion of U.S. women had previously been screened, or that
the criteria for referral differ: in 2000, 79.1 % of United States women aged 50+ reported
having had a mammogram during the past two years (23), whereas only 28% of the Danish
women aged 50+ were screened in the past two years before 2000.
Despite the perennial tradeoff between false- and true-positive examinations, diagnostic
mammography aims to detect as many cancers with as few false-positive exams as possible.
In the United States, for diagnostic mammograms, radiologists worry more about sensitivity
than specificity, because women already have clinical symptoms and their breast cancers
may be more advanced; so no one wants any additional delay in diagnosis. This contrasts
with screening mammography, where the number of false-positives tests needs to be
controlled, given the large number of women being screened, few of whom have cancer. The
advantage of using ROC analysis in evaluating test accuracy compared with separate
analyses of sensitivity and specificity is that the AUC provides an index of overall test
accuracy if sensitivity and specificity have equal weights. However, computing the AUC on
the 5-point BI-RADS scale to evaluate clinical performance has limitations (24–27).
Among 93,585 women included from the United States, 565 out of 3,773 breast cancers
were missed at the diagnostic mammography, and 6,117 women without breast cancer were
referred to biopsy. This shows that about 11 women had a false-positive test for each missed
cancer. In contrast, when the Danish sensitivity and specificity is applied to the same
number of women, 664 out of 3,773 breast cancers would have been missed, but only 1,227
women without breast cancer would have been referred to diagnostic workup. This shows
that only two women will have a false-positive test for each missed cancer. Denmark needs
to address the benefits and harms from missing cancers; and the United States needs to
address the large number of biopsies performed in women without cancer.
Our study has several strengths. One is the degree of complete collection of standardized
data for all diagnostic mammograms performed in Denmark in 2000 and for the BCSC.
Furthermore, to stabilize our estimates, we included many women from both countries. The
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BCSC data includes diverse areas of the United States and is representative of community
practice in the United States. Our study also had some limitations. As with all comparisons
between two health care delivery systems, we could not control subtle differences between
them. In the United States, the BI-RADS codes were assessed by the clinical radiologist and
guided the diagnostic process, while these codes were assessed retrospectively in Denmark
based on the free text dictated at the reading session. Compared with the United States,
Denmark had a more restrictive use of BI-RADS category 3 and a much larger proportion of
breast cancers in this category. Because the BI-RADS codes were inferred retrospectively in
Denmark based on the free texts, the codes might not fully reflect all management
recommendations. In the United States, inconsistencies in the BI-RADS assessment and
management recommendations for mammography are well documented (28;29). Access to
mammography also differs between the two countries. Because diagnostic mammography is
free and available in Denmark, women will not hesitate to seek care at the first sign of a
symptom. We could not adjust for previous screening and time elapsed since last screen,
which might have helped to explain some of the differences we found. We could not adjust
for breast density, a risk factor for breast cancer that can affect accuracy; however, we have
no reason to believe that the distributions vary between the two populations (30). We did not
have complete capture of ultrasound examinations in the United States.
In conclusion, this is the first study to compare diagnostic mammography performance as it
is practiced in community-based settings. Although the accuracy of diagnostic
mammography was high in both countries, important differences exist between performance
measures in the United States and in Denmark. Our findings therefore suggest that
additional comparative studies will be useful to improve diagnostic service to women with
signs and symptoms of breast cancer.
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AUC area under the ROC curve
BCSC Breast Cancer Surveillance Consortium
BI-RADS® Breast Imaging Reporting and Data System
CBE clinical breast examination
CC cranio-caudal projection
DCIS ductal carcinoma in situ
ML medio-lateral projection
MLO medio-lateral-oblique projection
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MRI magnetic resonance imaging
ROC receiver operating characteristic
FNA fine needle aspiration
CNB core needle biopsy
WHO World Health Organization
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Diagnostic mammography empirical receiver operating characteristic (ROC) curves for
Denmark and the United States, respectively. Empirical or observed sensitivity is plotted
against the empirical or observed false-positive rate (1 minus specificity) for each BI-
RADS© (Breast Imaging Reporting and Data System) criterion point. Starting from the
lower left, the cut points for the mammographic examination BI-RADS™ assessments being
called positive are 5, 4, 3, 2, and 1. AUC is area under the ROC curve.
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Table 1
Characteristics of study participants from United States (Breast Cancer Surveillance Consortium) and
Denmark.
United States Denmark
Study base 180 breast imaging facilities from 7
population-based mammography
registries of the BCSC
All 47 diagnostic mammography clinics in Denmark
(screening clinics not included)
Definition of diagnostic mammogram Mammograms recorded as
evaluation of breast problem
(symptomatic)
All mammograms from diagnostic clinics1
Study period 1999–2001 2000
Total number of women 93,585 51,313
Age distribution, years: number (%)2
 20–29 2997 (3.2) 1906 (3.7)
 30–39 19 632(21.0) 8710 (17.0)
 40–49 31 421 (33.6) 13 582 (26.5)
 50–59 20 147 (21.5) 14 871 (29.0)
 60–69 10 510 (11.2) 7653 (14.9)
 70–79 6725 (7.2) 3697 (7.2)
 80–89 2153 (2.3) 894 (1.7)
Breast cancer definition Histology-confirmed invasive
carcinoma or DCIS
Histology/cytology-confirmed invasive/DCIS
Breast cancer identification Linkage with cancer registries and
pathology databases
Linkage with nationwide cancer and pathology registries
Examinations supplemented with
ultrasound
37% to 52%3 74%
Breast cancer incidence4 97 (USA, white) 84 (Denmark)
1
Outside the two organized screening programmes, asymptomatic women can be referred to diagnostic mammography clinics for opportunistic
screening. This happened seldom, as the annual utilization rate of all diagnostic mammography (symptomatic and asymptomatic women together)
was only 2.7% in women aged >25 in 2000 (21).
2




Age-standardized rate per 100,000 (WHO World Standard Population) for the year 2000 (22).
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Table 3
Performance of diagnostic mammography in the United States and Denmark.
United States Denmark
True-negative tests (%) 83 695 (89.4) 47 252 (92.1)
True-positive tests (%) 3208 (3.4) 2807 (5.5)
False-negative tests (%) 565 (0.6) 599 (1.2)
False-positive tests (%) 6117 (6.5) 655 (1.3)
Sensitivity (%) 85.0 82.4
Specificity (%) 93.2 98.6
Accuracy (AUC) 0.912 0.950
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